ArticleScientific reports2025
Nomogram for predicting postpartum hemorrhage in women with hypertensive disorders of pregnancy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Maternal Outcomes Associated with Delayed Cord Clamping in Hypertensive Disorders of Pregnancy: A Cross-Sectional Study.Diseases (Basel, Switzerland) · 2026Article
- Development and Validation of a Predictive Nomogram for Postpartum Hemorrhage in Pregnant Women: A Retrospective Study.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postpartum hemorrhage (PPH) is a serious complication of hypertensive disorders of pregnancy (HDP) that can severely endanger maternal life. However, clinicians lack an HDP-specific, pre-delivery tool to quantify individual PPH risk. We aimed to develop and internally validate a nomogram for predicting PPH in patients with HDP. This retrospective single-center study included 480 women with HDP admitted between January 2022 and January 2025. PPH was defined as blood loss ≥ 500 mL after vaginal delivery or ≥ 1000 mL after cesarean section within 24 h. Patients were randomly assigned to a training set (n = 336) and a validation set (n = 144) in a 7:3 ratio. Clinical and laboratory variables, including systolic blood pressure (SBP), proteinuria, activated partial thromboplastin time (APTT), fibrinogen (FIB), 25-hydroxyvitamin D [25(OH)D], hepatocyte growth factor (HGF), and endothelin (ET), were analyzed by logistic regression to identify independent predictors for inclusion in the nomogram. Model performance was evaluated by area under the receiver operating characteristic curve (AUC), sensitivity, specificity, calibration curves, and decision curve analysis (DCA). Multivariate analysis indicated that SBP, proteinuria, APTT, and ET were independent risk factors for PPH in HDP patients, whereas FIB, 25(OH)D, and HGF were independent protective factors (P <0.05). The nomogram yielded an AUC of 0.895 (95% CI: 0.859-0.931; sensitivity 75.6%, specificity 86.2%) in the training set and 0.882 (95% CI: 0.811-0.953; sensitivity 78.9%, specificity 83.0%) in the validation set, with Hosmer-Lemeshow χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.